Send to:

Choose Destination
See comment in PubMed Commons below
Clin Pharmacol Ther. 2008 Jan;83(1):172-6. Epub 2007 Dec 12.

Cathepsin K inhibitors: a novel target for osteoporosis therapy.

Author information

  • 1Department of Clinical Pharmacology, Merck Research Laboratories, Rahway, New Jersey, USA.


Osteoporosis is characterized by low bone mass with skeletal fragility and an increased risk of fracture. This bone loss is brought about by an imbalance between bone resorption and formation. Cathepsin K is the most abundant cysteine protease expressed in the osteoclast and is believed to be instrumental in bone matrix degradation necessary for bone resorption. Cathepsin K inhibitors represent a novel target for developing agents to treat osteoporosis and other disorders characterized by increased bone resorption.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Write to the Help Desk